News | April 12, 2024
Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData
A significant proportion of healthcare professionals still tend to favor branded drugs
A significant proportion of healthcare professionals still tend to favor branded drugs
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
The company plans to add 1700 beds by FY27 through the organic route
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Subscribe To Our Newsletter & Stay Updated
